Our group focuses on translational neuropharmacology, with a particular interest in acquired epilepsy, pharmacoresistance, pain, and translational molecular imaging. Using refined rodent models, we investigate how epilepsy and drug resistance develop after brain injury and how these processes can be prevented, modified, or treated pharmacologically.
A central theme is the interaction between the brain and the periphery, including the blood–brain barrier, immune system, and gut–brain axis. We study how neuroinflammation and altered metabolism contribute to disease development and how they can be targeted through pharmacological approaches within a One Health perspective. Non-invasive PET/SPECT imaging enables us to monitor disease mechanisms and treatment responses longitudinally and at the systems level in vivo.
Systematic reviews help us evaluate existing evidence, support model refinement, and strengthen translational relevance. Our work also contributes to the refinement of animal models, including improved anesthesia, analgesia, pain assessment, and severity classification in neurosurgical mouse models.